|
Registered number: 10996079
PRECISION HEALTHTECH LTD (FORMERLY HEALTHY. IO (UK) LTD)
FINANCIAL STATEMENTS
INFORMATION FOR FILING WITH THE REGISTRAR
FOR THE PERIOD ENDED 22 DECEMBER 2025
|
|
PRECISION HEALTHTECH LTD (FORMERLY HEALTHY. IO (UK) LTD)
REGISTERED NUMBER: 10996079
BALANCE SHEET
AS AT 22 DECEMBER 2025
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Debtors: amounts falling due within one year
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Creditors: amounts falling due within one year
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Share based payment reserve
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with the provisions of FRS 102 Section 1A - small entities.
The financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime.
The Company has opted not to file the statement of comprehensive income in accordance with provisions applicable to companies subject to the small companies' regime.
The financial statements were approved and authorised for issue by the board and were signed on its behalf by:
................................................
Y Li
|
|
|
|
|
The notes on pages 2 to 11 form part of these financial statements.
|
|
PRECISION HEALTHTECH LTD (FORMERLY HEALTHY. IO (UK) LTD)
NOTES TO THE FINANCIAL STATEMENTS
FOR THE PERIOD ENDED 22 DECEMBER 2025
On 27 April 2026 a resolution was passed to change the name of the company from Healthy. IO (UK) Limited to Precision Healthtech Ltd.
Precision Healthtech Ltd (the "Company") is a private company limited by shares, incorporated in England and Wales. The Company's registered number is 10996079. The address of the Company's registered office is 89 High Street, Hadleigh, Ipswich, Suffolk, IP7 5EA.
The Company's principal activity during the period continued to be the provision of remote clinical testing and services enabled by smartphone technology.
2.Accounting policies
|
|
|
Basis of preparation of financial statements
|
The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with FRS 102 'The Financial Reporting Standard applicable in the UK and the Republic of Ireland' and the requirements of the Companies Act 2006. The disclosure requirements of Section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.
Effective from the 31 December 2024 year end, the company has chosen to early adopt the amendments to FRS 102 issued in the Periodic Review 2024, which are otherwise effective for accounting periods beginning on or after 1 January 2026. These amendments have been considered in the preparation of these financial statements.
The most significant impact of early adoption relates to the following areas:
Changes in the accounting for leases, where an on-balance sheet model has been applied for lessees, resulting in the recognition of right-of-use assets and lease liabilities. In line with the transitional provisions of FRS 102, the company has not restated prior year figures. Depreciation is charged so as to allocate the cost of assets over the period of the lease liability. On review, there were no on-balance sheet leases identified by the entity.
Revenue recognition is now based on the five-step model for revenue recognition from IFRS 15 Revenue from Contracts with Customers, with appropriate simplifications.
The preparation of financial statements in compliance with FRS 102 requires the use of certain critical accounting estimates. It also requires management to exercise judgment in applying the Company's accounting policies (see note 3).
The following principal accounting policies have been applied:
|
|
PRECISION HEALTHTECH LTD (FORMERLY HEALTHY. IO (UK) LTD)
NOTES TO THE FINANCIAL STATEMENTS
FOR THE PERIOD ENDED 22 DECEMBER 2025
2.Accounting policies (continued)
During the year, the Company paused trading in its Kidney Contracts, resulting in a reduction in turnover and the company has incurred a loss during this period. The directors are actively pursuing new contract opportunities.
The Company meets its day-to-day working capital requirements through its cash reserves and financial support provided by Precision Marketing Group Holdings Ltd, its parent company. The parent company has confirmed its intention and ability to provide financial support to enable the Company to meet its liabilities as they fall due for at least 12 months from the date of approval of these financial statements.
Having considered the forecasts and the expected ongoing support available from the wider group, the directors believe that the Company will have adequate resources to continue in operational existence for the foreseeable future. Accordingly, the financial statements have been prepared on the going concern basis.
|
|
|
Foreign currency translation
|
Functional and presentation currency
The Company's functional and presentational currency is GBP.
Transactions and balances
Foreign currency transactions are translated into the functional currency using the spot exchange rates at the dates of the transactions.
At each period end foreign currency monetary items are translated using the closing rate. Non-monetary items measured at historical cost are translated using the exchange rate at the date of the transaction and non-monetary items measured at fair value are measured using the exchange rate when fair value was determined.
Foreign exchange gains and losses resulting from the settlement of transactions and from the translation at period-end exchange rates of monetary assets and liabilities denominated in foreign currencies are recognised in profit or loss except when deferred in other comprehensive income as qualifying cash flow hedges.
Foreign exchange gains and losses that relate to borrowings and cash and cash equivalents are presented in the Statement of Comprehensive Income within 'finance income or costs'. All other foreign exchange gains and losses are presented in profit or loss within 'other operating income'.
|
|
PRECISION HEALTHTECH LTD (FORMERLY HEALTHY. IO (UK) LTD)
NOTES TO THE FINANCIAL STATEMENTS
FOR THE PERIOD ENDED 22 DECEMBER 2025
2.Accounting policies (continued)
Revenue is recognised to the extent that it is probable that the economic benefits will flow to the Company and the revenue can be reliably measured. Revenue is measured as the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes. The following criteria must also be met before revenue is recognised:
Sale of goods
Revenue from the sale of goods is recognised when all of the following conditions are satisfied:
∙the Company has transferred the significant risks and rewards of ownership to the buyer;
∙the Company retains neither continuing managerial involvement to the degree usually associated with ownership nor effective control over the goods sold;
∙the amount of revenue can be measured reliably;
∙it is probable that the Company will receive the consideration due under the transaction; and
∙the costs incurred or to be incurred in respect of the transaction can be measured reliably.
Interest income is recognised in profit or loss using the effective interest method.
Finance costs are charged to profit or loss over the term of the debt using the effective interest method so that the amount charged is at a constant rate on the carrying amount. Issue costs are initially recognised as a reduction in the proceeds of the associated capital instrument.
Defined contribution pension plan
The Company operates a defined contribution plan for its employees. A defined contribution plan is a pension plan under which the Company pays fixed contributions into a separate entity. Once the contributions have been paid the Company has no further payment obligations.
The contributions are recognised as an expense in profit or loss when they fall due. Amounts not paid are shown in accruals as a liability in the Balance Sheet. The assets of the plan are held separately from the Company in independently administered funds.
|
|
PRECISION HEALTHTECH LTD (FORMERLY HEALTHY. IO (UK) LTD)
NOTES TO THE FINANCIAL STATEMENTS
FOR THE PERIOD ENDED 22 DECEMBER 2025
2.Accounting policies (continued)
|
|
|
Current and deferred taxation
|
The tax expense for the period comprises current and deferred tax. Tax is recognised in profit or loss except that a charge attributable to an item of income and expense recognised as other comprehensive income or to an item recognised directly in equity is also recognised in other comprehensive income or directly in equity respectively.
The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the balance sheet date in the countries where the Company operates and generates income.
Deferred tax balances are recognised in respect of all timing differences that have originated but not reversed by the balance sheet date, except that:
∙The recognition of deferred tax assets is limited to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits; and
∙Any deferred tax balances are reversed if and when all conditions for retaining associated tax allowances have been met.
Deferred tax balances are not recognised in respect of permanent differences except in respect of business combinations, when deferred tax is recognised on the differences between the fair values of assets acquired and the future tax deductions available for them and the differences between the fair values of liabilities acquired and the amount that will be assessed for tax. Deferred tax is determined using tax rates and laws that have been enacted or substantively enacted by the balance sheet date.
Exceptional items are transactions that fall within the ordinary activities of the Company but are presented separately due to their size or incidence.
Tangible fixed assets under the cost model are stated at historical cost less accumulated depreciation and any accumulated impairment losses. Historical cost includes expenditure that is directly attributable to bringing the asset to the location and condition necessary for it to be capable of operating in the manner intended by management.
|
|
PRECISION HEALTHTECH LTD (FORMERLY HEALTHY. IO (UK) LTD)
NOTES TO THE FINANCIAL STATEMENTS
FOR THE PERIOD ENDED 22 DECEMBER 2025
2.Accounting policies (continued)
|
|
|
Tangible fixed assets (continued)
|
Depreciation is charged so as to allocate the cost of assets less their residual value over their estimated useful lives, using the straight-line method.
Depreciation is provided on the following basis:
|
|
|
|
|
Long-term leasehold property
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The assets' residual values, useful lives and depreciation methods are reviewed, and adjusted prospectively if appropriate, or if there is an indication of a significant change since the last reporting date.
Gains and losses on disposals are determined by comparing the proceeds with the carrying amount and are recognised in profit or loss.
Stocks are stated at the lower of cost and net realisable value, being the estimated selling price less costs to complete and sell. Cost is based on the cost of purchase on a first in, first out basis. Work in progress and finished goods include labour and attributable overheads.
At each balance sheet date, stocks are assessed for impairment. If stock is impaired, the carrying amount is reduced to its selling price less costs to complete and sell. The impairment loss is recognised immediately in profit or loss.
Short-term debtors are measured at transaction price, less any impairment. Loans receivable are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method, less any impairment.
|
|
|
Cash and cash equivalents
|
Cash is represented by cash in hand and deposits with financial institutions repayable without penalty on notice of not more than 24 hours. Cash equivalents are highly liquid investments that mature in no more than three months from the date of acquisition and that are readily convertible to known amounts of cash with insignificant risk of change in value.
Short-term creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method.
|
|
PRECISION HEALTHTECH LTD (FORMERLY HEALTHY. IO (UK) LTD)
NOTES TO THE FINANCIAL STATEMENTS
FOR THE PERIOD ENDED 22 DECEMBER 2025
2.Accounting policies (continued)
|
|
|
Provisions for liabilities
|
Provisions are recognised when an event has taken place that gives rise to a legal or constructive obligation, a transfer of economic benefits is probable and a reliable estimate can be made.
Provisions are measured as the best estimate of the amount required to settle the obligation, taking into account the related risks and uncertainties.
Increases in provisions are generally charged as an expense to profit or loss.
The Company only enters into basic financial instrument transactions which result in the recognition of financial assets and liabilities like trade and other debtors and creditors, and loans to related parties.
|
|
|
Employee share ownership plan
|
The parent entity administers an ESOP share scheme of which the UK employees also receive a benefit.
Where share options are awarded to employees, the fair value of the options at the date of grant is calculated over the vesting period. Non-market vesting conditions are taken into account by adjusting the number of equity instruments expected to vest at each Statement of Financial Position date so that, ultimately, the cumulative amount recognised over the vesting period is based on the number of options that eventually vest. Market vesting conditions are factored into the fair value of the options granted.
Based on the above calculations a recharge is made to the UK entity from the parent for the yearly cost of the scheme which is recognised in the Statement of Comprehensive Income with the other entry being a share based payment reserve.
|
|
The average monthly number of employees, including directors, during the period was 16 (2024 - 26).
|
|
|
PRECISION HEALTHTECH LTD (FORMERLY HEALTHY. IO (UK) LTD)
NOTES TO THE FINANCIAL STATEMENTS
FOR THE PERIOD ENDED 22 DECEMBER 2025
|
|
Long-term leasehold property
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Charge for the period on owned assets
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
PRECISION HEALTHTECH LTD (FORMERLY HEALTHY. IO (UK) LTD)
NOTES TO THE FINANCIAL STATEMENTS
FOR THE PERIOD ENDED 22 DECEMBER 2025
|
|
Finished goods and goods for resale
|
|
|
|
|
|
|
|
|
|
During the year, the Company paused trading in its Kidney Contracts and as part of the cessation, inventories with a carrying value of £87,187 were determined to be obsolete and were written off in full.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Prepayments and accrued income
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash and cash equivalents
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Creditors: Amounts falling due within one year
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Amounts owed to group undertakings
|
|
|
|
|
|
|
|
|
|
Other taxation and social security
|
|
|
|
|
|
|
|
|
|
Accruals and deferred income
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
PRECISION HEALTHTECH LTD (FORMERLY HEALTHY. IO (UK) LTD)
NOTES TO THE FINANCIAL STATEMENTS
FOR THE PERIOD ENDED 22 DECEMBER 2025
Share based payment reserve
The Share based payment reserve represents the cumulative charge in respect of the share options awarded to employees of the Company.
Profit and loss account
Retained earnings represents the cumulative profit and losses of the Company, less the payment of dividends.
The Company participates in an Employee Share Option Scheme for the benefit of certain employees. The options are granted over the shares of the parent undertaking with an exercise price equal to the actual market value of each share as at the date of grant and can only be exercised while the option holder remains an employee of the Company and in limited circumstances.
The employees were given a 30 day notice period to exercise any share options prior to the sale of the company post period end after which date all remaining share options were withdrawn at the date of sale.
The Company operates a defined contribution pension scheme. The assets of the scheme are held separately from those of the Company in an independently administered fund. The pension cost charge represents contributions payable by the Company to the fund and amounted to £39,739 (2024 - £55,533). Contributions totalling £23,085 (2024 - £23,915) were payable to the fund at the Statement of Financial Position date and are included in other creditors.
|
|
Related party transactions
|
|
|
The Company has taken advantage of the exemption available in accordance with Section 33 'Related party disclosure' of FRS 102 not to disclose transactions entered into between two or more members of a group that are wholly owned.
|
|
|
Post balance sheet events
|
On 23 December 2025, the entire issued share capital of the Company was acquired by Precision Marketing Group Holdings Limited, a company incorporated in England and Wales. As a result of the acquisition, the Company became a wholly owned subsidiary of Precision Marketing Group Holdings Limited.
Subsequent to the acquisition, on 27 April 2026, the Company changed its name from Healthy. IO (UK) Ltd to Precision Healthtech Ltd.
The acquisition and subsequent change of name occurred after the reporting date and therefore has not been reflected in the amounts recognised in these financial statements.
|
|
PRECISION HEALTHTECH LTD (FORMERLY HEALTHY. IO (UK) LTD)
NOTES TO THE FINANCIAL STATEMENTS
FOR THE PERIOD ENDED 22 DECEMBER 2025
The immediate and ultimate parent undertaking at the end of the accounting period is Healthy. IO Ltd., a Company incorporated in Israel, whose registered office is 8 Yizhak Sadeh 2, Tel Aviv, Israel.
Post period end on 23 December 2025 the ultimate parent entity became Precision Marketing Group Holdings Ltd, a company registered in England and Wales who acquired 100% of the share capital of the company.
There is considered to be no ultimate controlling party of the Group.
The auditors' report on the financial statements for the period ended 22 December 2025 was unqualified.
The audit report was signed on 22 September 2026 by Louise Cherry ACA (Senior Statutory Auditor) on behalf of Hillier Hopkins LLP.
|